The Role of Antihistamines in the Treatment of Vasomotor Rhinitis by Phil Lieberman
NAR CONSENSUS PANEL PROCEEDINGS, PART 2
The Role of Antihistamines in the Treatment of
Vasomotor Rhinitis
Phil Lieberman, MD
Background: The pathogenesis of vasomotor rhinitis is not under-
stood. It is unlikely that antihistamines, based on their H1 antagonist
activity alone, would be effective in this disorder.
Methods: Nonetheless, at least one double-blind, placebo-con-
trolled multicenter trial has found that intranasal azelastine relieves
symptoms of this disorder better than placebo. The mechanism
responsible for its beneficial effect in nonallergic rhinitis is unclear
but probably relates to “anti-inflammatory/antiallergic” activities.
Results: Such mechanisms have been demonstrated for a number
of different oral antihistamines, but often the concentrations
required in vitro are higher than those that are normally achieved
in vivo using recommended dosing. It has been postulated that
intranasal administration, which can achieve high local levels,
might be a factor responsible for enhancing the “anti-inflamma-
tory/antiallergic” properties.
Conclusions: Interpreting this information allows one to conclude
that antihistamines may be potentially effective agents in vasomotor
rhinitis, and are more likely to be so when administered intranasally,
despite the fact that data documenting this beneficial effect are
sparse.
Key Words: antihistamines, vasomotor rhinitis, nonallergic
rhinitis, anti-inflammatory activities, nonallergic activities
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INTRODUCTION
Perhaps the best way to introduce the topic of the role ofantihistamines in the management of vasomotor rhinitis
is to quote a statement from the ARIA Workshop Reports.1
In a section entitled, “Noninfectious, Nonallergic Rhini-
tis,” the ARIA Report states: “Our knowledge in this area
is poor. The response to H1-antihistamines in patients who
have sneezing as a predominant symptom points at hista-
mine as an important mediator, but H1-antihistamines are
generally ineffective in most patients.” Why then a review
of the role of antihistamines in the management of vaso-
motor or nonallergic rhinitis?
The reason for the inclusion of antihistamines as a
potentially beneficial therapeutic agent in vasomotor rhinitis
(VMR) is a seminal study by Banov et al2 demonstrating that
azelastine was effective in managing this disorder. The
Banov article was published in the same year as the ARIA
guidelines (2001), and, thus, was not included in the ARIA
document. This article changed our perspective on the poten-
tial use of antihistamines, at least those administered intra-
nasally, in the treatment of VMR.3–6 In addition, a suggestion
that oral antihistamines might be helpful in the treatment of
VMR was generated by Purello-D’Ambrosio et al.7 The
Purello-D’Ambrosio study compared loratadine flunisolide
to flunisolide  placebo in patients suffering from a subcat-
egory of nonallergic rhinitis (NAR), nonallergic rhinitis with
eosinophilia (NARES). The loratadine  flunisolide treated
group fared better than the flunisolide  placebo group.
Improvements were noted in sneezing and rhinorrhea,
prompting the authors to conclude that loratadine “improves
the effectiveness of flunisolide in treatment of NARES.”
Thus, there clearly is justification for a review of antihista-
mine therapy in the management of VMR.
SOME PUTATIVE MECHANISMS OF ACTION
OF ANTIHISTAMINES IN THE TREATMENT
OF VMR
The proposed mechanisms by which antihistamines
might be effective in the therapy for VMR are include:
1. “Classic” H1 antagonist (reverse agonist) activity as be-
lieved to be responsible for their beneficial effects in
allergic rhinitis
2. Antagonism of other histamine receptors, most probably
via the H2 and, perhaps, H3 receptors
3. Other “anti-inflammatory/antiallergic” actions
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A discussion of each of these potential mechanisms of action
can shed some light on the observations, noted above,2,7 that
antihistamine treatment may have a salutary effect on the
symptoms of VMR.
Potential Benefit via H1 Receptor Antagonism
Histamine has 4 receptor types (H1, H2, H3, and H4),
which are all G protein-coupled.8 Antihistamines used in the
treatment of allergic rhinitis all have as their most prominent
activity, antagonism (reverse agonism) of the H1 receptor.
The characteristics of the H1 receptor are shown in Table 1.
The difficulty in postulating a role for H1 antagonism in the
treatment of nonallergic rhinitis is the scant evidence that
histamine plays a role in this disorder.9 Thus, it is unlikely
that the demonstrated effects of antihistamines on VMR
symptoms are related to H1 receptor antagonism (reverse
agonism).
Antagonism of the Effects of H2, H3, and H4
Receptors
The H2 Receptor
The H2 receptor is a member of the heptahelical recep-
tor family (Table 2). There is some evidence that H2 recep-
tors mediate dilation of nasal blood vessels.10 Wood-Baker et
al showed that stimulation of the H2 receptor can cause nasal
obstruction presumably because of vasodilatation. Subjects
were pretreated with oral cetirizine or ranitidine in a double-
blind, randomized manner after which histamine was applied
to the nasal mucosa. They measured the concentration of total
protein and albumin in nasal lavage fluid and nasal airway
resistance before and after histamine challenge. Ranitidine
reduced the maximum increase in nasal airway resistance, but
this effect was only significant when combined with cetiriz-
ine. The increase in nasal lavage protein and albumin was
almost completely abolished by cetirizine; ranitidine had far
less effect. They concluded that H2 receptor antagonism had
little, if any, effect on vascular permeability but did seem to
have some effect on nasal obstruction.
Further evidence was found for a role of H2 receptor
stimulation in the production of symptoms of rhinitis via an
investigation by Shelton and Eisor.11 These investigators
applied histamine, a specific H1 receptor agonist (betahistine,
and a specific H2 receptor agonist) impromidine, to the nasal
mucosa of 11 normal subjects and 4 patients with rhinitis.
Sneezing, nasal irritation, and hypersecretion were induced
only by histamine and the H1 receptor agonist, betahistine.
Nasal airway resistance was increased by all 3 agents, with
histamine being the most potent effector and with the H2
receptor agonist, impromidine, producing a greater effect
than the H1 receptor agonist, betahistine. Thus, this study
clearly showed a role for H2 receptor stimulation in the
production of nasal congestion.





Location of receptors Multiple sites throughout the body including:
Smooth muscle bronchi and gastrointestinal
tract, cardiac tissue, blood vessels, sensory
nerves, endothelium, central nervous system
Chromosome location 3p25, 3p14–21
Signal conduction
induces
Increased cyclic GMP, increased intracellular
cytosolic calcium, activation of phospholipase




Over 40 exist. Examples of “second
generation” include cetirizine, desloratadine,
fexofenadine, loratadine, azelastine,
olopatadine
Examples of “first generation” antihistamines
are chlorpheniramine, diphenhydramine,
pyribenzamine, and others
Activities Increases vascular permeability producing a fall
in blood pressure, flush, headache, and reflex
tachycardia; itch; smooth muscle contraction
in bronchi and gastrointestinal tract;
stimulation of vagal nerve receptors
producing reflex smooth muscle contraction
in airways; cough via stimulation of sensory
nerves in airways; eosinophil chemotaxis;
decreased AV node conduction time;
enhancement of release of histamine and




Sneezing, itching, rhinorrhea, and perhaps some
degree of nasal congestion via increased
vascular permeability with leakage of fluid
into the tissues and vasodilatation?





Location of receptors Widely expressed including: Mucosa of
stomach, cardiac tissue, uterus, smooth
muscle vascular bed, epithelium of mucosa
of nose, submucosal glands in nose, central








Burimamide, cimetidine, dimaprit, famotidine,
nizatidine, ranitidine, and others (it should
be noted that a number of different H1
antagonists also show affinity for the H2
receptor
Activities Increased gastric acid secretion; increases
vascular permeability producing a fall in
blood pressure, flush, headache, and reflex
tachycardia; stimulate mucus production in
the lungs; direct chronotropic effect on
atrium and inotropic action on ventricle;
relaxation of esophageal sphincter;
stimulation of suppressor T-cells; decrease in
neutrophil and basophil chemotaxis and
activation; proliferation of lymphocytes;
activity of NK cells
Nasal symptoms
produced
Antagonism of the H2 receptor could
potentially reduce the effect of histamine on
nasal airway swelling, producing nasal
decongestion
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A number of H1 antagonists demonstrate H2 receptor
binding. For example, Sharif et al compared the activity of
several H1 antagonists on the H2 receptor.12 They evaluated
pyrilamine, ketotifen, pheniramine, antazoline, olopatadine,
and levocabastine for their affinities for the H1, H2, and H3
receptors and found promiscuity among the drugs, demon-
strating that H1 receptor antagonists can also bind H2 and H3
receptors.
Bielory et al13 reviewed the relative H1 and H2 receptor
affinities of several H1 antagonists and reported a hierarchy
of affinities for each receptor (Table 3).
Thus, at least on a theoretical basis, antagonism of the
H2 receptor could have some effect on the nasal congestion
of VMR; and H1 antagonists can exert antagonism on the H2
receptor. Once again, however, a word of caution: there is no
clear-cut evidence that histamine plays a role in producing
symptoms of VMR.
The H3 Receptor
The H3 receptor is a G protein-coupled receptor (Table
4) located primarily at presynaptic sites on histaminergic
nerve terminals. Histamine stimulates these terminals causing
inhibition of activity. In the nose, by acting on the H3
receptor, histamine can reduce the release of norepinephrine
from sympathetic nerves, an effect that could diminish the
tonic role of sympathetic stimulation in the homeostatic
maintenance of nasal airway patency.
H3 antagonists have been shown to reverse nasal con-
gestion induced by the intranasal application of histamine.
Taylor-Clark et al14 investigated the mechanisms by which
histamine produced nasal blockage. They applied histamine
and specific histamine receptor agonists intranasally in
healthy human subjects and assessed their effect on airway
congestion by acoustic rhinometry. Oral pretreatment with
cetirizine had only a partial effect on nasal blockage. Dima-
prit, an H2 agonist, produced nasal congestion that was
reversed by ranitidine. A combination of cetirizine and rani-
tidine caused greater inhibition of nasal blockage than ceti-
rizine alone. An H3 agonist, R-alpha-methylhistamine, pro-
duced nasal blockage that was not inhibited by cetirizine or
ranitidine.
The H3 antagonist, thioperamide, reversed the R-alpha-
methylhistamine induced nasal blockage. Thioperamide
alone had no effect on nasal blockage caused by histamine,
but in the presence of cetirizine, thioperamide further
reduced the histamine-induced nasal blockage. They con-
cluded that nasal congestion because of the application of
histamine to healthy nasal mucosa results from activity at
H1, H2, and H3 receptors.
Therefore, there is a third potential means by which
antagonism of histamine could favorably affect nasal conges-
tion. However, again, for this therapy to be effective, hista-
mine would have to play a role in producing congestion in
VMR, and H1 antagonists would have to show some promis-
cuity, being active at the H2 and H3 receptors as well.
The H4 Receptor
The H4 receptor (Table 5) is mentioned only for the
sake of thoroughness. H4 receptors can in many instances be
considered anti-inflammatory. They are found on a number of
cells, and down-regulate histamine-induced inflammatory re-
sponses in these cells. There is no evidence that H1 antago-
nists act at the H4 receptor. Thus, little can be said at this time
TABLE 3. Relative Histamine Receptor Binding Affinities








Ketotifen 1.3 1155 2277
Emedastine 1.3 49,067 12,430
Desloratadine 4 ND ND
Cetirizine 6.3 ND ND
Azelastine 6.8 ND ND
Epinastine 9.8* 4030* ND
Diphenhydramine 12.5 1600 25,000
Olopatadine 32 100,000 79,400
Loratadine 35 ND ND
Levocabastine 56 23,500 4597
Fexofenadine 83 ND ND
Pyrilamine 0.8 9510 1016
Chlorpheniramine 1.4 7980 3103
Pheniramine 34 14,567 10,567
Antazoline 38 44,433 42,400
Ranitidine 46,100 187 10,537
Cimetidine 6190 2377 20,750
Thioperamide 280,000 57,967 1.1
Methylhistamine 138,000 72,100 1.4
Histamine 180,000 18,350 4.5
Ki is the dissociation constant based on the Cheng–Prussof equation, Ki 1/4 IC50/
(1 Þ L/Kd), such that a lower value denotes higher affinity binding. IC50 is the
concentration of drug needed to produce 50% inhibition of the receptor binding.
The lower the value the higher the affinity (13).
ND, no data.
*Reported as the IC50.





Location of receptors Mainly expressed on presynaptic nerves in
the peripheral sympathetic adrenergic
system and histaminergic nerves in the
central nervous system. Receptors can be








None available clinically: Thioperamide,
alobenpropit, and others Very little data
regarding effect of H1 antagonists on the
H3 receptor are available (13)
Activities Opposes bronchoconstriction and gastric
acid; suppression of norepinephrine release
at presynaptic nerve endings
Nasal symptoms
produced
Can produce nasal decongestion by blocking
effect of histamine on adrenergic
postsynaptic receptors
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about the potential role of H4 antagonism in the therapy for
VMR.
Anti-Inflammatory Activities of Antihistamines
It is well known that antihistamines have effects which
have been called “anti-inflammatory” or “antiallergic.” These
effects have been well documented and have been demon-
strated for many different molecules including those admin-
istered orally and by intranasal application. Some of the in
vitro effects may be of very little clinical importance because,
in many instances, the concentration of antihistamine neces-
sary to produce the effects are higher than those commonly
achieved by oral administration of recommended doses.
However, in some instances, for intranasally administered
antihistamine, the concentrations achieving an “anti-inflam-
matory effect” are obtained at recommended doses. This may
explain the fact that the only antihistamine to date approved
for use in VMR in the US is azelastine, which is administered
intranasally. Some of the presumably most important “anti-
inflammatory/antiallergic” activities of antihistamines are
noted in Table 6 and summarized below.
Prevention of Mast Cell/Basophil
Degranulation
Perhaps the most well studied anti-inflammatory/anti-
allergic effect of antihistamines is related to their ability to
inhibit mast cell and basophil mediator release. This effect
has been demonstrated both in vitro and in vivo.8 Both
preformed mediators and newly synthesized mediator release
can be prevented by antihistamines. This effect has been
shown not only for IgE-mediated release, induced by both
allergen and anti-IgE, but also for secretagogues including
compound 48/80, substance P, concanavalin A, and calcium
ionophore A23187.
In general, all second-generation antihistamines show
some inhibition of inflammatory mediator release from mast
cells and basophils in vitro, but there is a great deal of
heterogeneity between activity of these drugs in terms of the
concentration required, the experimental conditions em-
ployed, and the degranulation stimulus.
For example, Okayama et al studied the effects of
terfenadine, ketotifen, and cetirizine on human lung, tonsil, and
skin mast cells stimulated immunologically with anti-IgE, and
found varying results depending on the drug studied.15
Both azelastine and olopatadine have clearly been
shown to diminish basophil and mast cell degranulation.
Azelastine has been shown to inhibit the release of histamine
from both human and animal mast cells induced by various
stimuli including anti-IgE, antigen, calcium ionophores, and
compound 48/80. In vivo this agent has been demonstrated to
prevent synthesis and/or release of mediators including leu-
kotrienes, tosyl arginine, methyl esterase, oxygen free radi-
cals, platelet activating factor, and superoxide anion.16
Olopatadine has also shown mast cell stabilizing activ-
ity inhibiting the release of histamine, tryptase, tumor necro-
sis factor-, and prostaglandin D2.17 Thus, the prevention of
mast cell and basophil degranulation is a well documented
characteristic of a number of different antihistamines. With
intranasal antihistamines, this effect has been shown to occur
in vivo after intranasal application in human beings.
Down-Regulation of the Expression of
Adhesion Molecules
The down-regulation of intracellular adhesion mole-
cule ICAM-1 has been demonstrated for levocabastine,
fexofenadine, terfenadine, and desloratadine in vitro.18
Perhaps more important, because of the greater clinical
applicability, is the ability of antihistamines to reduce the
expression of ICAM-1 and the subsequent inflammatory
cell infiltration in the eyes and nose in vivo. Azelastine,
levocabastine, cetirizine, oxatomide, terfenadine, fexofe-
nadine, mizolastine, olopatadine, and loratadine have all
been shown to diminish ICAM-1 expression on either
nasal and/or conjunctival epithelial cells. This can result in
a reduction of inflammatory infiltrate into these mucosal
tissues. These effects have been observed after both aller-
gen challenge and during natural antigen exposure.18





Location of receptors Eosinophils, neutrophils, basophils,
mast cells, spleen, liver, lung












None available clinically: Has
homology with H3 receptor and is
also antagonized by same drugs
Activities Chemotaxis and chemokinesis of
mast cells and eosinophils;







Since histamine can up regulate
inflammation on cells such as
eosinophils, H4 antagonists may
have a beneficial role in this
regard
TABLE 6. “Anti-inflammatory/Antiallergic” Activities of
Antihistamines
Prevent mast cell degranulation




Enhance inflammatory cell apoptosis
Reduce inflammatory cytokine expression
Decrease neurogenic enhancement of inflammation
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Regulation of Chemotaxis
Fexofenadine, ketotifen, cetirizine, loratadine, terfe-
nadine, and desloratadine have been shown to diminish
eosinophil chemotaxis in vitro, and ketotifen, terfenadine,
azelastine, and cetirizine have demonstrated a decrease in
neutrophil chemotaxis in vivo.8
Enhancement of Apoptosis of Inflammatory
Cells
Enhancement of programmed cell death for eosinophils
has been demonstrated for ketotifen and cetirizine.8 In addi-
tion, azelastine administered orally has been found to reduce
peripheral eosinophilia in a patient with the hypereosinophilic
syndrome. Ito, et al, reported a case of hypereosinophilic
syndrome in a 9-year-old, in which the administration of
azelastine significantly reduced peripheral eosinophilia while
simultaneously markedly diminishing the serum interleukin 5
levels.19
Reduction of the Inflammatory Cytokine
Expression
As with the other anti-inflammatory/antiallergic effects
noted above, antihistamines have been shown to diminish the
expression of a number of different cytokines, both in vivo
and in vitro. These effects have been shown for IL4, IL6, IL8,
IL13, and tumor necrosis factor- and other inflammatory
cytokines.8,20
Suppression of Neurogenic Enhancement of
Inflammation
Neurogenic inflammation or an imbalance in neural
control of the nasal airways has been postulated to play a role
in the production of VMR.9 Inhibition of the inflammatory
effects of neurogenic stimulation therefore might be expected
to diminish symptoms of VMR. Antihistamines have been
shown to favorably affect neurogenic inflammation. For ex-
ample, substance P has been shown to be released during
antidromic stimulation. Oral administration of azelastine has
been found to reduce substance P levels in bronchial lavage
and nasal washings produced by allergen challenge.21
Thus, in summary, antihistamines have been shown to
exert a number of different anti-inflammatory/antiallergic
effects. These effects could clearly have a salutary effect on
nasal symptoms. It has been shown that at least some patients
with VMR demonstrate inflammatory infiltrates in the nasal
mucosa.22–25 Therefore, it would not be unreasonable to
assume that inhibition of the inflammatory activity resulting
in these infiltrates could be responsible for the improvement
in VMR symptoms shown in at least one double-blind pla-
cebo-controlled study.2
CLINICAL IMPLICATIONS
Based on a summation of the above information, there
is little doubt that antihistamine therapy could be potentially
effective in the treatment of VMR, especially through anti-
inflammatory/antiallergic effects. However, there has been a
dearth of clinical confirmation of the efficacy of antihista-
mines, especially oral antihistamines, in VMR.
Oral Antihistamines
Trials of oral antihistamines are scarce and have
yielded, in general, inconsistent and for the most part, disap-
pointing results.7,26–28 Two of these studies evaluated an
antihistamine as adjunctive therapy either with a deconges-
tant26 or a topical steroid.7 Broms and Malm found that
phenylpropanolamine alone in a dose of 100 mg reduced
nasal airway resistance, but that this drug in a dose of 50 mg
combined with an oral antihistamine had no effect on nasal
airway resistance.26 Purello-D’Ambrosio7 found loratadine
added to the beneficial effect of flunisolide. Two other studies
looked at antihistamines as monotherapy.27,28 Mullarkey27
reported that topical steroids were superior to antihistamines
in the treatment of patients with NARES; Rinne et al28 came
to a similar conclusion in a long-term study comparing
topical budesonide to cetirizine in NARES patients.
Intranasal Antihistamines
The only antihistamine currently approved in the US
for use in VMR is azelastine, an agent with broad-based
pharmacologic activities in addition to its H1 receptor antag-
onist action. Food and Drug Association (FDA) approval was
based on 2 pivotal double-blind, placebo-controlled trials
demonstrating efficacy.2 Another multicenter, double blind,
randomized, parallel-group study by Gehanno et al confirmed
the efficacy of azelastine in VMR,22 and 2 large open-label
studies employing patient questionnaires demonstrated the
beneficial effect of azelastine in patients with allergic rhinitis,
mixed rhinitis, and VMR.23,24
There is also a study employing topical levacobastine in
a small number of patients, some with allergic rhinitis and
some with VMR. Levocabastine was found to be superior to
placebo for symptoms of nasal discharge and sneezing but not
for congestion in the VMR group.25
A Closer Look
Because the FDA approval of azelastine for the treat-
ment of nonallergic rhinitis was granted based on 2 studies, as
noted above, by Banov, et al,2 it would be of value to take a
closer look at these investigations. Both studies were multi-
center placebo-controlled trials of azelastine for the treatment
of nonallergic VMR, and both used identical protocols. More
than 200 patients were evaluated; the response rates were
between 82 and 85%. It is of note that the response to placebo
in these studies was quite high, 73%. This is not unexpected
because placebo saline nasal spray has shown to exert some
beneficial effect in this disorder.
All of the patients in these trials had experienced
symptoms of VMR for at least one year, had negative skin
tests to a mixed panel of seasonal and perennial allergens, and
had no eosinophils as evaluated by nasal cytology. After a 1
week, single-blind, placebo lead-in period, patients who met
the symptom severity qualification criteria were randomized
to receive either azelastine nasal spray or placebo. Patients
recorded the severity of their symptoms on diary cards each
morning and evening, using a 4-point symptom rating scale.
The primary efficacy variable was the overall reduction from
baseline in the total VMR symptom score over the 21 day,
double-blind, treatment period.
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In both trials, azelastine was superior to placebo in
reducing VMR symptom score from baseline (study 1, P 
0.002; study 2, P  0.005). Significant improvement oc-
curred within the first week. In addition, of note is that
azelastine was superior to placebo in all 4 symptoms mea-
sured, including nasal congestion.
CONCLUSIONS
Data are sparse regarding the effects of antihistamines
on the symptoms of VMR. Nonetheless, there is theoretical
rationale, based upon the activities of antihistamines (espe-
cially their anti-inflammatory/antiallergic activities) to sup-
port the hypothesis that they may be effective agents in
treating VMR. This hypothesis was confirmed in a study of
azelastine in the treatment of this disorder. However, to date
there is no convincing evidence that oral antihistamines are
helpful, in general, as monotherapy and only inconsistent and
sparse data supporting their use as adjunctive treatment given
with topical coticosteroids or decongestants.
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